

ASX ANNOUNCEMENT

26 JULY 2017



Amendment to Request for Trading Halt

Cogstate advises that the request for trading halt submitted to the ASX this morning included an erroneous reference to a placement.

Cogstate confirms that it has not made any placement of shares.

Cogstate expects to be able to update the market in respect of its 510(k) submission before the market opens on Thursday 27 July 2017.

The corrected letter is attached to this announcement.

For further information contact:

Brad O'Connor
Cogstate Chief Executive Officer
+613 9664 1300 or 0411 888 347
boconnor@cogstate.com



COGSTATE

ASSESS • MONITOR • IMPROVE

26 July 2017

James Gerraty
Advisor, Listings Compliance
ASX Limited
Level 4
North Tower, Rialto
525 Collins Street
Melbourne VIC 3000

Dear James

Cogstate Ltd (**Company**) requests an immediate trading halt be granted by ASX with respect to its securities (ASX code: CGS).

The trading halt is requested by Cogstate pending an announcement to the market in connection with its 510(k) submission to the U.S. Food and Drug Administration (FDA) for the Cogstate COGNIGRAM™ System.

In accordance with ASX Listing Rule 17.1, the Company provides the following information:

- (a) The trading halt is necessary as otherwise trading in the Company's securities might occur while the market as a whole is not reasonably informed.
- (b) The Company requires the trading halt from 26 July 2017 and continuing until the earlier of the Company making an announcement to ASX concerning the 510(k) submission and the commencement of trading on Friday, 28 July 2017.
- (c) The Company expects an announcement concerning the 510(k) submission will be made prior to the commencement of trading on Thursday, 27 July 2017.
- (d) The Company is not aware of any reason why the trading halt should not be granted.
- (e) The Company is not aware of any other information necessary to inform the market about the trading halt.

Yours faithfully

Brad O'Connor
Managing Director